OC9 Stock Chart & Stats
€32.20
-€0.60(-1.44%)
At close: 4:00 PM EST
€32.20
-€0.60(-1.44%)
Day’s Range― - ―
52-Week Range€24.00 - €43.80
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€1.63B
Enterprise Value€1.44K
Total Cash (Recent Filing)€290.96M
Total Debt (Recent Filing)€202.18M
Price to Earnings (P/E)92.2
Beta<0.01
Next Earnings
Jul 30, 2026EPS Estimate
0.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.44
Shares Outstanding45,478,910
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-12.17
Price to Book (P/B)1.69
Price to Sales (P/S)1.76
P/FCF Ratio23.97
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€57.09Price Target Upside77.30% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)1.7
Revenue Forecast (FY)€1.09B
Bulls Say, Bears Say
Bulls Say
Balance-sheet DeleveragingMaterial reduction in leverage meaningfully lowers financial risk and interest burden, giving Omnicell durable financial flexibility. A cleaner balance sheet supports multi-quarter investments in product rollouts, opportunistic buybacks or M&A, and better resilience to healthcare spending cycles.
Strong Free Cash FlowSustained, growing free cash flow provides a durable funding source for R&D, commercial expansion and platform rollouts without relying on external financing. Robust FCF increases optionality to fund Titan XT shipments, OmniSphere deployment and continued balance-sheet repair while absorbing cyclical revenue swings.
Product & Recurring Revenue TractionNew hardware (Titan XT) plus cloud platform (OmniSphere) create a multi-year upgrade and SaaS expansion avenue. Initial XT orders and firm ARR guidance indicate durable commercial momentum and higher recurring services mix, which should improve revenue visibility and increase customer stickiness over time.
Bears Say
Very Thin ProfitabilityNear-break-even net margin and weak ROE limit the company's ability to convert revenue growth into shareholder returns and provide little buffer against cost or demand shocks. Sustained low profitability constrains reinvestment capacity and raises sensitivity to margin pressure from tariffs or mix shifts.
Slow Titan XT Revenue CadenceLong hospital capital cycles mean high-margin hardware replacement revenue will be backloaded and uncertain quarter-to-quarter. That structural pacing risk delays realization of the product's economic benefits and makes near-term revenue and margin predictability dependent on multi-year procurement timelines.
Retail Segment PressureOngoing weakness in the retail pharmacy end-market can depress consumables, services and recurring revenue growth tied to EnlivenHealth. This concentration risk may slow ARR expansion and reduce diversification, making results more cyclically sensitive and raising execution risk for long-term service revenue growth.
Omnicell News
OC9 FAQ
What was Omnicell’s price range in the past 12 months?
Omnicell lowest stock price was €24.00 and its highest was €43.80 in the past 12 months.
What is Omnicell’s market cap?
Omnicell’s market cap is €1.63B.
When is Omnicell’s upcoming earnings report date?
Omnicell’s upcoming earnings report date is Jul 30, 2026 which is in 3 days.
How were Omnicell’s earnings last quarter?
Omnicell released its earnings results on Apr 28, 2026. The company reported €0.483 earnings per share for the quarter, beating the consensus estimate of €0.291 by €0.192.
Is Omnicell overvalued?
According to Wall Street analysts Omnicell’s price is currently Undervalued.
Does Omnicell pay dividends?
Omnicell does not currently pay dividends.
What is Omnicell’s EPS estimate?
Omnicell’s EPS estimate is 0.41.
How many shares outstanding does Omnicell have?
Omnicell has 45,478,910 shares outstanding.
What happened to Omnicell’s price movement after its last earnings report?
Omnicell reported an EPS of €0.483 in its last earnings report, beating expectations of €0.291. Following the earnings report the stock price went down -1.25%.
Which hedge fund is a major shareholder of Omnicell?
Currently, no hedge funds are holding shares in DE:OC9
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Omnicell Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€57.09 (77.30% Upside)
€57.09 (77.30% Upside)
Blogger Sentiment
Bullish
DE:OC9 Sentiment 100%
Sector Average 65%
Sector Average 65%
Technicals
SMA
Positive
20 days / 200 days
Momentum
45.75%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-6.85%
Trailing 12-Months
Company Description
Omnicell
Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an automated dispensing system; XTExtend, a console swap for its XT cabinets; and Central Pharmacy Dispensing Service for the medication dispensing process. The company also provides Central Med Automation Service for medication dispensing; IV Compounding Service, an in-house compounding system; specialty pharmacy services, including turnkey solution to help health systems establish, manage, and optimize an entity-owned specialty pharmacy; EnlivenHealth platform to digitally enable retail and community pharmacies; medication adherence solutions comprising consumables and medication packaging systems; and technology implementation, customer education and training, program management, and related offerings to professional services. In addition, it offers post-installation support and maintenance via phone and/or web, on-site service, parts, and access to software upgrades; software and hardware products for full traceability of medicines and medical supplies throughout the healthcare system; OmniSphere, a cloud-based platform. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.
OC9 Company Deck
OC9 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong operational and financial momentum: robust top-line growth (+15% YoY), outsized improvement in profitability (non-GAAP EBITDA and EPS nearly doubling year-over-year), improved free cash flow, and constructive commercial traction following the Titan XT and OmniSphere launches. Management raised FY profitability guidance while maintaining revenue and bookings targets. Key risks discussed include near-term pacing of Titan XT adoption due to long capital cycles, a $12M tariff headwind, a lower cash balance after debt repayment and buybacks, and some potential quarter-to-quarter margin/revenue variability as expenses are phased throughout the year. On balance, positive execution, raised guidance, and a strong pipeline outweigh the timing and macro/cyclical headwinds.View all DE:OC9 earnings summariesOC9 Stock 12 Month Forecast
Average Price Target
€57.09
▲(77.30% Upside)